3 in 1: Genome Editing, Biomarkers and NGS Data Analysis conferences
On 6-7 February 2017, San Diego (CA), will host three MnM annual conferences on Genome Editing and Engineering, Biomarkers, and NGS Data Analysis and Informatics.
2nd Annual Genome Editing & Engineering Conference
Genome editing holds the promise of a breakthrough in the area of pharmaceutical science, since the discovery of the CRISPR/Cas systems. The conference brings together the key industry leaders and researchers to address the concepts, challenges & applications of the genome editing tools like CRISPR/Cas9, TALENs.
Case studies and sessions will reveal the potential application of genome editing tools from the modern biomedical & therapeutic applications. Special emphasis on CRISPR system addressing the concept, technology, challenges like integration of genome, off-target effects, and delivery systems.
Go to the conference website to learn more about the details of the upcoming conference.
2nd Annual Biomarker Conference
The recent success of companion diagnostics along with the increasing regulatory pressure for better identification of the target population has created an extraordinary spur for drug discovery companies to invest in novel strategies for biomarker discovery. Also, the confluence of immunology and oncology tributaries has triggered a biomarker turbulence that is novel to the cancer community.
The pursuit to drive precision medicine and the quest to refine a biomarker model for immuno-oncology drug development, the 2nd Annual Biomarker Conference aims to gather experts from pharma, bio-pharma companies and research institutes to discuss current challenges and opportunities in biomarker discovery, CDx, NGS, regulatory and reimbursement issues and novel technologies.
Key highlights includes: translational medicine and biomarkers, NGS and circulating biomarkers, biomarkers in Immuno-Oncology, liquid biopsies etc. Read more on the conference website.
2nd Annual NGS Data Analysis and Informatics Conference
Next -generation sequencing (NGS) technology revolution has brought influx of large-scale data where storage and management, processing and integration, validation for quality, has become a challenge in biomedical industry. FDA and other regulatory bodies have been working to develop a regulatory framework for NGS applications in various fields based on validated analytical standards that would ensure that NGS tests produce accurate and reliable results.
In order to find answers to biomedical questions ranging from evolutionary heritage to the functioning of cellular molecular machinery and address the challenges faced, NGS data analysis and bioinformatics solutions has to be discussed among all the stakeholders.
We will send a discount code for 20% off the registration fees in the DNAdigest newsletter soon.